

From: DailyWealth Trader customerservice@exct.stansberryresearch.com
Subject: Pfizer's \$10 Billion Ticket to Making Obesity Drugs
Date: November 13, 2025 at 11:01 AM
To: ron.shane3@gmail.com

SA



Delivering World-Class Financial Research Since 1999



Pfizer's \$10 Billion Ticket to Making Obesity Drugs

Pfizer (PFE) owns drugs that bring in billions of dollars each year...

Its blood thinner, Eliquis, made \$2 billion in the third quarter of 2025. And it has drugs across the spectrum, from pneumonia vaccine Prevnar to cancer drug Ibrance.

Pfizer was also a huge player in the fight against COVID-19. Its breakthrough vaccine was the first one approved by the U.S. Food and Drug Administration ("FDA").

Pfizer's history of developing drugs that make it to market is strong. But since the pandemic, it has struggled to find another blockbuster.

That has been a dark cloud over this stock for years... But last Friday, Pfizer took action to change that.

It bought biotech startup Metsera for roughly \$10 billion.

Metsera has several drugs that have a chance to turn into big winners. If just one hits, Pfizer will have a new revenue source worth billions. So this deal is good news for our

position in the pharma giant...

We first recommended "[trading for income](#)" on Pfizer in January 2024.

The stock was trading at dirt-cheap valuations and showing signs of a new uptrend forming. We were assigned shares the next month and have sold calls on it several times.

The stock has mostly traded sideways since our initial recommendation. We're up 7.6% so far. But the Metsera deal adds a new catalyst for upside from here.

Let's break down what Pfizer is getting in this deal...

Metsera is developing anti-obesity drugs. And its main drug in later-stage trials is Met-097i.

It's a GLP-1 drug just like Ozempic or Wegovy – two drugs that Novo Nordisk (NVO) sells to help fight obesity. The two drugs brought in a combined \$25 billion in revenue for Novo in 2024.

But they also cause nausea and vomiting in a lot of folks. Reports show that 44% of adult Wegovy users have nausea. Around 20% of Ozempic of users experience nausea. Plus, Wegovy had 24% of adults report vomiting during clinical trials.

Metsera's MET-097i is showing better results so far. It wrapped up its Phase IIb trial in September. And the numbers are exactly what you want to see in a promising drug...

The trial showed a 14.1% mean weight loss after 28 weeks. The highest individual number was 26.5%. And the 14% weight loss over 28 weeks showed no signs of plateauing... meaning that the weight loss could continue steadily after 28 weeks.

At the same time, only 13% of folks are having nausea. And 11% reported vomiting.

That's a much better profile than Wegovy.

It's also important to note that Met-097i is being tested as a once-a-month injection. Today, folks have to get weekly injections. So it would be a lot less work to achieve similar weight-loss results with fewer negatives.

Of course, this drug is still in clinical trials. And it could have a poor showing in Phase III that prevents it from getting FDA approval. But so far, the numbers look good.

Plus, this is one of several drugs that Metsera is developing for weight loss. If just one makes it to market, it could add another \$10 billion a year in revenue or more for Pfizer.

After all, Ozempic brought in \$17.5 billion in revenue in 2024. And even if there's more competition ahead, a drug with similar weight loss and fewer side effects will take market share.

In the past 12 months, Pfizer has brought in \$62.7 billion in revenue... which means a weight-loss drug can have a big impact on revenues.

Today, Pfizer is even cheaper than when we opened our position in January 2024. It trades at a price-to-earnings (P/E) ratio of 9.6... one of the lowest levels it has traded at in the past decade.

For comparison, its average P/E ratio since 2015 is 16.1. The stock would have to rise 68% just to trade at that average.

In short, we continue to rate Pfizer a buy. It's a proven business trading for dirt-cheap valuations. And the Metsera deal adds a new upside element heading into 2026.

If you haven't bought shares of Pfizer, we recommend doing so today.

– Chris Igou

TRADING NOTES

- The iShares Silver Trust (SLV) rose 4% yesterday to \$48.32. If you own shares from [our March 19, 2020 recommendation](#), you're up 328%. Continue holding with a 25% trailing stop, which is \$36.88.
- Royal Gold (RGLD) climbed 3.3% yesterday to \$193.51. If you've followed our advice since [our August 2, 2023 recommendation](#), you're up 72.9%. Continue holding with a 25% trailing stop, which is \$148.36.

- Wheaton Precious Metals (WPM) rose 3.5% yesterday to \$107.77. If you've followed our advice since [our May 30, 2025 recommendation](#), you're up 25.4%. Continue holding with a 30% trailing stop, which is \$79.29.
- The Invesco WilderHill Clean Energy Fund (PBW) fell 2.4% yesterday to \$31.88. If you've followed our advice since [our July 24, 2025 recommendation](#), you're up 29.8%. Continue holding with a 25% trailing stop, which is \$26.86.
- Digital Realty Trust (DLR) fell 2.8% yesterday to \$163.90. If you bought shares based on [our July 30, 2025 recommendation](#), you're down 2.3%. Continue holding with a 25% trailing stop, which is \$133.24.
- We update the *DailyWealth Trader (DWT)* [portfolio](#) every Tuesday afternoon using Monday's closing prices. To check returns and stop losses on our open positions, or to find links to the most recent issue for one of our recommendations, click the link above.

YOU MIGHT BE INTERESTED IN...

[Which Stock Will the White House Buy Next?](#)

The richest entity in history – the U.S. government – is now charging into the stock market... buying shares of public companies... and sending them soaring hundreds of percent. One jumped 90% overnight. Another surged 200% in just 24 HOURS. Which stock is next in the crosshairs? [Learn more here before the next buy order hits.](#)



TRAINING CENTER

- Take five minutes before you open a trade and five more after you exit the trade to fill out a [Trade Record](#). It works by addressing two of the biggest mistakes traders make: 1) not understanding why you're making a trade, and 2) not having a defined exit strategy. It also does a lot of the calculations for you.

TOP OPEN POSITIONS

The prices on these trades might have changed... but we still like the setups. So if you're looking to put "new money" to work right now, start here. For options, [see our](#)

you're looking to put new money to work right now, start here. For options, [see our guidelines on building your own trades](#) using today's prices. For stocks, [do not enter your stop losses into the market](#).

Wednesday, November 12, 2025

[Earn a 3.2% Payout as the U.S. Dollar Sinks](#)

Build your own options trade on the iShares MSCI Emerging Markets Fund (EEM)

Wednesday, October 8, 2025

[A New Regime Is Boosting This Beloved Retail Stock](#)

Build your own options trade on Nike (NKE)

Friday, October 3, 2025

[The 25-Year Battery Is Just the Start](#)

Buy the Amplify Lithium & Battery Technology Fund (BATT)

Thursday, September 25, 2025

[Buy This Market Maker as It Gains Momentum](#)

Buy CBOE Global Markets (CBOE)

Tuesday, September 16, 2025

[Triple-Digit Gains Are in Reach as a New Boom Kicks Off](#)

Buy ProShares Ultra FTSE China 50 (XPP)

Wednesday, September 3, 2025

[Finding Double-Digit Upside in Buffett's Final Footsteps](#)

Buy Lennar (LEN)

Thursday, August 28, 2025

[The Surprise Trade to Dominate in Late 2025](#)

Buy the iShares Russell 2000 Fund (IWM)

Wednesday, August 20, 2025

[Collect 4.8% on the NFL's New Streaming Partner](#)

Build your own options trade on the Walt Disney Company (DIS)

Wednesday, July 30, 2025

[A Second Chance for This AI Architecture Stock](#)

Buy Digital Realty Trust (DLR)

Thursday, July 24, 2025

[A Shot at Triple-Digit Gains in This Hated Market](#)

Buy the Invesco WilderHill Clean Energy Fund (PBW)

Friday, June 27, 2025

[Buy This Breakout While Another Asset Struggles](#)

Buy the abrdn Physical Palladium Shares Fund (PALL)

Wednesday, June 11, 2025

[Join the Hyperscalers' Bullish AI Bet](#)

Buy shares of the VanEck Semiconductor Fund (SMH)

Thursday, June 5, 2025

[A Shot at 50% Gains From the IPO Resurgence](#)

Buy shares of the Renaissance IPO Fund (IPO)

Friday, May 30, 2025

[Buy This World-Class Streamer in Precious Metals](#)

Buy Wheaton Precious Metals (WPM)

Tuesday, May 20, 2025

[Catch a 50%-Plus Gain in This Market](#)

Buy shares of the iShares MSCI Brazil Fund (EWZ)

Tuesday, May 13, 2025

[This Little-Known Giant Is Set to Double](#)

Buy shares of MercadoLibre (MELI)

Wednesday, April 23, 2025

[How to Profit as the 'Cola Wars' Evolve](#)

Build your own pairs trade on Coca-Cola (KO) and PepsiCo (PEP)

Tuesday, March 25, 2025

[Buy This Beaten-Down Sector as Momentum Turns Bullish](#)

Buy the Vanguard Information Technology Fund (VGT)

Wednesday, November 20, 2024

[Buy This Beaten-Down Sector as Momentum Turns Bullish](#)

[The 'Widow-Maker Trade' Is Worth Double Digits](#)

Buy the iShares 20+ Year Treasury Bond Fund (TLT)

Wednesday, August 2, 2023

[Position Yourself for the Long Term as Gold Takes Off](#)

Buy shares of Royal Gold (RGLD)

Monday, May 22, 2023

[How to Profit as Our U.S. Market System Turns to Buy Mode](#)

Buy shares of the Vanguard S&P 500 Fund (VOO)

Wednesday, March 25, 2020

[Here's Why Gold Will Hit \\$3,300 per Ounce... And How You Can Profit](#)

Buy the SPDR Gold Shares (GLD)

For more ideas from *DailyWealth Trader*, [access our full archive here](#).

Tell us what you think of this content



We value our subscribers' feedback. To help us improve your experience, we'd like to ask you a couple brief questions.

[Click here to rate this e-mail](#)

You are receiving this e-mail because you are a paid subscriber to *DailyWealth Trader*. If you no longer wish to receive this e-mail, you can cancel or modify your subscription by contacting customer service at 888-261-2693 (U.S.) or 443-839-0986 (international) Monday-Friday, 9 a.m.-5 p.m. Eastern time. Or you can e-mail us at info@stansberryresearch.com.

If you have forgotten your username or password, please [click here](#).

Stansberry Research welcomes comments or suggestions at feedback@stansberryresearch.com. This address is for feedback only. Please note: The law prohibits us from giving personalized financial advice.

© 2025 Stansberry Research. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Stansberry Research, 1125 N Charles St, Baltimore, MD 21201 stansberryresearch.com.

Any brokers mentioned constitute a partial list of available brokers and is for your information only. Stansberry Research does not recommend or endorse any brokers, dealers, or investment advisors.

Stansberry Research forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Stansberry Research (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation.

This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.